MedTrace Logo

Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate

NCT00880672 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-06-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether dutasteride may influence the expression of angiogenesis factors such as hypoxia inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF) in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH).

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

dutasteride

5mg, oral, daily, 2-4 weeks

Sponsors & Collaborators

  • The Korean Urological Association

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jae-Seung paick, MD, PhD · Dept. of Urology, Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-12-31
Completion
2009-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00880672 on ClinicalTrials.gov